Cite
Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy.
MLA
Li, Mengshi, et al. “Pre-Clinical Evaluation of Biomarkers for the Early Detection of Nephrotoxicity Following Alpha-Particle Radioligand Therapy.” European Journal of Nuclear Medicine and Molecular Imaging, vol. 51, no. 5, Apr. 2024, pp. 1395–408. EBSCOhost, https://doi.org/10.1007/s00259-023-06559-9.
APA
Li, M., Robles-Planells, C., Liu, D., Graves, S. A., Vasquez-Martinez, G., Mayoral-Andrade, G., Lee, D., Rastogi, P., Marks, B. M., Sagastume, E. A., Weiss, R. M., Linn-Peirano, S. C., Johnson, F. L., Schultz, M. K., & Zepeda-Orozco, D. (2024). Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy. European Journal of Nuclear Medicine and Molecular Imaging, 51(5), 1395–1408. https://doi.org/10.1007/s00259-023-06559-9
Chicago
Li, Mengshi, Claudia Robles-Planells, Dijie Liu, Stephen A Graves, Gabriela Vasquez-Martinez, Gabriel Mayoral-Andrade, Dongyoul Lee, et al. 2024. “Pre-Clinical Evaluation of Biomarkers for the Early Detection of Nephrotoxicity Following Alpha-Particle Radioligand Therapy.” European Journal of Nuclear Medicine and Molecular Imaging 51 (5): 1395–1408. doi:10.1007/s00259-023-06559-9.